Osteoporosis in patients with prostate cancer on long-term androgen deprivation therapy: An increasing but under-recognised problem

BJU International

Volumn 106, Issue 5, 2010, Pages 726-727

  Langley, Ruth ^a   Price, Pat ^b   Pollock, Philip ^a   Abel, Paul D ^b  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ESTRADIOL; ESTROGEN; FLUTAMIDE; GONADORELIN AGONIST; MONOCLONAL ANTIBODY; POLYESTRADIOL PHOSPHATE; PROSTATE SPECIFIC ANTIGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TESTOSTERONE;

ANDROGEN DEPRIVATION THERAPY; ANEMIA; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER SURVIVOR; CARDIOVASCULAR DISEASE; CASTRATION; CLINICAL DECISION MAKING; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FIRST PASS EFFECT; HORMONE INHIBITION; HOT FLUSH; HUMAN; LETTER; LONG TERM CARE; METABOLIC SYNDROME X; MUSCLE ATROPHY; ORCHIECTOMY; OSTEOPOROSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL;

ANDROGEN ANTAGONISTS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; OSTEOPOROSIS; PROSTATIC NEOPLASMS;

EID: 77955891265     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09605_1.x     Document Type: Letter

References (11)

1. Brown JE, Sherriff JM, James ND. Osteoporosis in patients with prostate cancer on long-term androgen deprivation therapy: an increasing but under-recognised problem. BJU Int 2010 105 : 1042 3
2. Kanis JA, Oden A, Johansson H, Borgstrom F, Strom O, McCloskey E. FRAX and its applications to clinical practice. Bone 2009 44 : 734 43
3. Smith MR. Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes 2007 14 : 247 54
4. Freedland SJ, Eastham J, Shore N. Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer. Prostate Cancer and Prostatic Dis 2009 12 : 333 8
5. Byar DP. Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973 32 : 1126 30
6. Von Schoultz B, Carlstrom K, Collste L et al. Estrogen therapy and liver function - metabolic effects of oral and parenteral administration. Prostate 1989 14 : 389 95
7. Nakamura T, Imai Y, Matsumoto T et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 2007 130 : 811 23
8. Hedlund PO, Damber JE, Hagerman I et al. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol 2008 42 : 220 9
9. Ockrim JL, Lalani EN, Banks LM et al. Transdermal estradiol improves bone density when used as single agent therapy for prostate cancer. J Urol 2004 172 : 2203 27
10. Langley RE, Godsland IF, Kynaston H et al. Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer. BJU Int 2008 102 : 442 5
11. MRC Clinical Trials Unit. PATCH (MRC PRO9): A randomised control trial of transcutaneous oestrogen patches versus LHRH analogues in prostate cancer. Available at: http://www.ctu.mrc.ac.uk/research-areas/study-details.aspx?s=23. Accessed July 2010.